|
|
|||
| |||||||||||||||||||||||||||||||||||||
Fran Hawthorne, senior contributing editor of Institutional Investor and a veteran writer covering health care, is not shy about expressing her opinions concerning the successes and failures of the regulatory agency that oversees approximately one quarter of the U.S. economy. Along the way, however, she presents the reader with a thoughtful and relatively balanced discussion of numerous issues with which the Food and Drug Administration (FDA) has been involved during its 100-year history. A prominent theme is that the FDA increasingly has ventured beyond adjudication of scientific matters into controversies involving issues of public policy and ethics. That may not
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |